Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Jun 2021
After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug
3 June 2021 - In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug after ...
Posted by Michael Wonder on 07 Jun 2021
EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome
7 June 2021 - EMA’s COVID-19 taskforce (COVID-ETF) is advising health care professionals in the EU to consider recommendations by learned ...
Posted by Michael Wonder on 07 Jun 2021
TGA investigating Pfizer jabs for children over 12
7 June 2021 - Australia’s medical regulator is considering allowing children over the age of 12 to be vaccinated with ...
Posted by Michael Wonder on 07 Jun 2021
New regulatory arrangements support businesses and health care professionals to communicate and incentivise COVID-19 vaccination
7 June 2021 - The TGA has implemented arrangements to facilitate the communication of information about approved COVID-19 vaccines. ...
Posted by Michael Wonder on 07 Jun 2021
Post-market review of medicines for smoking cessation – public consultation on the draft report
7 June 2021 - The draft report for the post-market review of medicines for smoking cessation is available for public comment ...
Posted by Michael Wonder on 06 Jun 2021
The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price.
3 June 2021 - When Amber Freed heard in 2020 that a drug might help save her young child from ...
Posted by Michael Wonder on 06 Jun 2021
NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness
3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...
Posted by Michael Wonder on 06 Jun 2021
Pharmacy Guild asks for right to give jab
6 June 2021 - Pharmacists say the COVID-19 immunisation program could be accelerated by three months if they could administer ...
Posted by Michael Wonder on 06 Jun 2021
FDA’s decision on Biogen Alzheimer’s drug will be a watershed moment for the agency — and the biotech industry
4 June 2021 - In the coming days the FDA will make one of its most important — and controversial — ...
Posted by Michael Wonder on 06 Jun 2021
GP bulk billing services at record highs
6 June 2021 - More Australians than ever are getting the medical care they need at no cost to themselves, with ...
Posted by Michael Wonder on 06 Jun 2021
Patients set to pay thousands more as rebates cut in raft of radical Medicare changes
6 June 2021 - A chaotic attempt to modernise the 38 year old Medicare system could see patients hit with higher ...
Posted by Michael Wonder on 05 Jun 2021
Alzheimer’s drug poses a dilemma for the FDA
5 June 2021 - If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. ...
Posted by Michael Wonder on 05 Jun 2021
Newly approved obesity drug Wegovy holds promise, but faces reimbursement challenges
5 June 2021 - On 4 June, the FDA approved Novo Nordisk’s obesity drug Wegovy (semaglutide), a glucagon-like peptide 1 receptor ...
Posted by Michael Wonder on 05 Jun 2021
Put Canadians first by suspending the implementation of harmful drug pricing regulations
4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...
Posted by Michael Wonder on 05 Jun 2021
Could big pharma actually lose this fight over drug prices? It's Biden's call.
3 June 2021 - More than 20 years ago, when I was the press secretary for then-Congressman Bernie Sanders, I rode ...